FOR IMMEDIATE RELEASE
SAN DIEGO (November 27, 2017) – TriLink BioTechnologies, a leader in oligonucleotide and mRNA synthesis for research, diagnostics and therapeutics, announced today that Michael Houston, Ph.D., has joined the company as chief scientific officer. In this role he is responsible for the company’s R&D as well as scientific thought leadership.
Houston holds a Ph.D. in bioorganic chemistry and has worked for a range of biotechnology and pharmaceutical companies, including PhaseRx, Marina Biotech, Ascent Therapeutics and Nastech Pharmaceutical. He specializes in oligonucleotide synthesis and therapeutic development.
"Houston will be a real asset to TriLink BioTechnologies,” said Carl Hull, CEO of Maravai LifeSciences. “He previously worked for one of our customers, so he brings a valuable perspective to our company."
About TriLink BioTechnologies
Founded in 1996, TriLink BioTechnologies is a global leader in the synthesis of high-quality nucleic acid and mRNA products for research, diagnostics, therapeutics and OEM customers. TriLink BioTechnologies’ products are instrumental in the discovery and development processes in gene and oligonucleotide therapy, nucleoside chemotherapy and diagnostics. The company is ISO 9001 certified and is compliant with ICH Q7, 21 CFR 210 and 21 CFR 820. TriLink BioTechnologies is headquartered in San Diego, Calif., where it also maintains its manufacturing facilities. The company was acquired by Maravai LifeSciences in 2016.
About Maravai LifeSciences
Maravai LifeSciences is committed to catalyzing the growth of successful, entrepreneurial, life science companies by providing expertise, capital, processes and systems. Maravai LifeSciences companies provide tools and services to pharmaceutical and biopharmaceutical research and development companies to enable breakthrough discoveries and improvements in human well-being. The Maravai LifeSciences portfolio includes Vector Laboratories, TriLink BioTechnologies, Cygnus Technologies and Glen Research. Maravai LifeSciences is a portfolio company of GTCR, a leading private equity firm focused on investing in growth companies in financial services, technology and information services and healthcare.
# # #
Contacts for the media:
David Weber, Chief Commercial Officer